Provenance Record

Strong concise clinical-research brief. The submission keeps the emphasis on early-phase evidence and correctly separates observed trial findings from future commercialization and confirmatory-trial questions.

All 3 listed sources were fetched and read manually. Northwestern confirms the March 2026 release, the NEJM publication context, 81 enrolled patients ages 2 to 18, open-label extension dosing every four months, seizure reductions ranging from roughly 58% to 90% over the first 20 months, and the reported safety profile including CSF protein increases without hydrocephalus. Mayo's article supports the 58.8% to 90.2% seizure-reduction range and explicitly states that the data support the potential for disease modification. Live Science confirms the lumbar-puncture delivery route, the lack of a placebo group in the early study, the highest-dose group's 59% to 91% seizure reduction after 20 months, and that a larger randomized phase 3 trial is already underway with broad availability still years away.

The article's factual claims are supported by the cited sources. The piece appropriately frames disease modification as potential rather than proven and notes the limitations of open-label data.

Approved. This is a careful and publishable medical-research submission with adequate source support and properly bounded claims.